Global Platelet Rich Plasma Market By Type (Pure Platelet-Rich Plasma or Pure PRP (P-PRP), Leukocyte and Platelet-Rich Plasma (L-PRP), Pure Platelet-Rich Fibrin (P-PRF), Leukocyte and Platelet-Rich Fibrin (L-PRF)); By Application(Orthopaedics, Sports medicine, Wound healing, Aesthetic surgery, Dentistry, Otolaryngology, Neurosurgery, Ophthalmology, Urology, Prolotherapy, Cardiothoracic , Maxillofacial surgery, Others); By End Use (Hospitals, Clinics, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The study of the human body has seen massive developments in recent years. The ability of the human body to heal by itself has resulted in the growth of a new technology known as platelet rich plasma therapy. It is form of regenerative medicine which can harness the self healing capacity of the human body, and augment the growth factors that the body uses to heal itself. Platelets, which is also referred to as thrombocytes, are a component of the human blood that is responsible for causing blood clots, and to perform other healing functions. An individual's own platelets are used for the accelerated healing of tendons, muscles, joints and ligaments, etc., which have been injured. Furthermore, platelet rich plasma therapy is also being used in skincare, especially for hair growth in individuals. The rise in demand for self healing using an individual's own platelets, coupled with the advancement in centrifugation therapy that allows medical practitioners to separate plasma rich platelets from human blood for injections, is leading to the growth of the global platelet rich plasma market.
COVID-19 Impact
The COVID-19 pandemic has affected the lives of billions of individuals around the globe. The healthcare system was overburdened during the initial phase of the pandemic, and government bodies were struggling to provide proper care for the patients affected by coronavirus. Various treatment methods were being explored for fighting the virus, as it badly affects people with comorbidities. Since the virus was relatively new in nature, and with the absence of a vaccine during the initial months, healthcare practitioners were using various methods for tacking the spread of the virus which has resulted in the death of over 4.5 million individuals thus far. One such treatment method that was in the clinical trial phase is that of autologous activated platelet-rich plasma (aaPRP) therapy. It contains various anti-inflammatory cytokines which has the potential to suppress cytokine release syndrome (CRS), which is an aftermath of the coronavirus. The growth in COVID-19 cases, and the use of platelet rich plasma therapy for COVID-19 therapeutics is expected to positively impact the growth of the global platelet rich plasma market.
In terms of revenue, platelet rich plasma market was valued at US$ 578.23 Mn in 2020 growing at a CAGR of 15.65% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Platelet Rich Plasma Market Revenue & Forecast, (US$ Million), 2015 – 2029
End-Use Outlook:
Platelet rich plasma therapy can be availed from hospitals and clinics, amongst other places. Medical grade centrifuges that can separate platelet rich plasma from human blood are being increasingly used in speciality clinics, especially for hair growth. Differential centrifugation allows the end-users to use accelerated force to sediment various cellular components on the basis of their specific gravity differences. In recent years, speciality clinics focussing on hair transplant and hair growth have seen considerable growth, especially in regions like North America, Middle East, and Asia Pacific. Clinics are expected to show considerable growth in the forecast years in the global platelet rich plasma market, and this growth will be mainly driven by the rising demand for plasma-based treatment methods amongst individuals.
Region Outlook:
As far as the regions are concerned, North America accounted for the highest share in the global platelet rich plasma market in 2020. The region is home to numerous companies that are offering platelet rich plasma services, and countries like the U.S. and Canada have a well-established healthcare network consisting of speciality hospitals, general hospitals and clinics, amongst others, which ensures a regular stream of revenue for the market participants. Furthermore, there is a higher awareness regarding platelet rich plasma therapy amongst healthcare practitioners and individuals, which further aids the growth of the platelet rich plasma market in North America. Atlas Health Medical Group, which is based in the U.S., has got a team of experts that provide platelet rich plasma therapy to the end-users. However, the high cost of platelet rich plasma therapy in the U.S. needs to be addressed, and the reduction of costs can attract more individuals to this treatment method in the coming years. The cost of a single platelet rich plasma therapy session is between US$ 500 to US$ 2,500, and multiple sittings may be required for the treatment to bear fruit. However, the Asia Pacific platelet rich plasma therapy market is expected to show the highest growth during the forecast years in the global platelet rich plasma therapy market, boosted by the rising demand for this therapy in countries like India, China and Malaysia, amongst others.
Competitive Landscape
The report provides both, qualitative and quantitative research of global platelet rich plasma market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global platelet rich plasma market are Atlas Health Medical Group, DePuySynthes, EmCyte Corporation, Glofinn America, LLC, Stryker, Terumo BCT, Inc., Zimmer Biomet, Medsor Impex, AdvaCare Pharma, PRP Labs, amongst others.
Global Platelet Rich Plasma Market
By Type
- Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
- Leukocyte and Platelet-Rich Plasma (L-PRP)
- Pure Platelet-Rich Fibrin (P-PRF)
- Leukocyte and Platelet-Rich Fibrin (L-PRF)
By Application
- Orthopaedics
- Sports medicine
- Wound healing
- Aesthetic surgery
- Dentistry
- Otolaryngology
- Neurosurgery
- Ophthalmology
- Urology
- Prolotherapy
- Cardiothoracic
- Maxillofacial surgery
- Others
By End Use
- Hospitals
- Clinics
- Others
By Region
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Platelet Rich Plasma Market
6.
Market
Synopsis: Platelet Rich Plasma Market
7.
Platelet
Rich Plasma Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Platelet Rich Plasma Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Platelet Rich Plasma Market
7.6. Impact of Covid-19 on Platelet Rich Plasma
Market
8.
Global
Platelet Rich Plasma Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global Platelet Rich Plasma Market Revenue
(US$ Mn)
8.2. Global Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
8.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.1.3.
Market
Forecast, 2021 - 2029
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1.
Market
Estimation, 2015 - 2020
8.2.1.5.1.2.
Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1.
Market
Estimation, 2015 - 2020
8.2.1.5.2.2.
Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1.
Market
Estimation, 2015 - 2020
8.2.1.5.3.2.
Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1.
Market
Estimation, 2015 - 2020
8.2.1.5.4.2.
Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1.
Market
Estimation, 2015 - 2020
8.2.1.5.5.2.
Market
Forecast, 2021 - 2029
8.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.2.3.
Market
Forecast, 2021 - 2029
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1.
Market
Estimation, 2015 - 2020
8.2.2.5.1.2.
Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1.
Market
Estimation, 2015 - 2020
8.2.2.5.2.2.
Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1.
Market
Estimation, 2015 - 2020
8.2.2.5.3.2.
Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1.
Market
Estimation, 2015 - 2020
8.2.2.5.4.2.
Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1.
Market
Estimation, 2015 - 2020
8.2.2.5.5.2.
Market
Forecast, 2021 - 2029
8.2.3. Pure Platelet-Rich Fibrin (P-PRF)
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.3.3.
Market
Forecast, 2021 - 2029
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1.
Market
Estimation, 2015 - 2020
8.2.3.5.1.2.
Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1.
Market
Estimation, 2015 - 2020
8.2.3.5.2.2.
Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1.
Market
Estimation, 2015 - 2020
8.2.3.5.3.2.
Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1.
Market
Estimation, 2015 - 2020
8.2.3.5.4.2.
Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1.
Market
Estimation, 2015 - 2020
8.2.3.5.5.2.
Market
Forecast, 2021 - 2029
8.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
8.2.4.3.
Market
Forecast, 2021 - 2029
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1.
Market
Estimation, 2015 - 2020
8.2.4.5.1.2.
Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1.
Market
Estimation, 2015 - 2020
8.2.4.5.2.2.
Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1.
Market
Estimation, 2015 - 2020
8.2.4.5.3.2.
Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1.
Market
Estimation, 2015 - 2020
8.2.4.5.4.2.
Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1.
Market
Estimation, 2015 - 2020
8.2.4.5.5.2.
Market
Forecast, 2021 - 2029
8.3. Key Segment for Channeling Investments
8.3.1. By Type
9.
Global
Platelet Rich Plasma Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
9.2.1. Orthopaedics
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.1.3.
Market
Forecast, 2021 - 2029
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1.
Market
Estimation, 2015 - 2020
9.2.1.5.1.2.
Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1.
Market
Estimation, 2015 - 2020
9.2.1.5.2.2.
Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1.
Market
Estimation, 2015 - 2020
9.2.1.5.3.2.
Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1.
Market
Estimation, 2015 - 2020
9.2.1.5.4.2.
Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1.
Market
Estimation, 2015 - 2020
9.2.1.5.5.2.
Market
Forecast, 2021 - 2029
9.2.2. Sports medicine
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.2.3.
Market
Forecast, 2021 - 2029
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1.
Market
Estimation, 2015 - 2020
9.2.2.5.1.2.
Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1.
Market
Estimation, 2015 - 2020
9.2.2.5.2.2.
Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1.
Market
Estimation, 2015 - 2020
9.2.2.5.3.2.
Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1.
Market
Estimation, 2015 - 2020
9.2.2.5.4.2.
Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1.
Market
Estimation, 2015 - 2020
9.2.2.5.5.2.
Market
Forecast, 2021 - 2029
9.2.3. Wound healing
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.3.3.
Market
Forecast, 2021 - 2029
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1.
Market
Estimation, 2015 - 2020
9.2.3.5.1.2.
Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1.
Market
Estimation, 2015 - 2020
9.2.3.5.2.2.
Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1.
Market
Estimation, 2015 - 2020
9.2.3.5.3.2.
Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1.
Market
Estimation, 2015 - 2020
9.2.3.5.4.2.
Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1.
Market
Estimation, 2015 - 2020
9.2.3.5.5.2.
Market
Forecast, 2021 - 2029
9.2.4. Aesthetic surgery
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.4.3.
Market
Forecast, 2021 - 2029
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1.
Market
Estimation, 2015 - 2020
9.2.4.5.1.2.
Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1.
Market
Estimation, 2015 - 2020
9.2.4.5.2.2.
Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1.
Market
Estimation, 2015 - 2020
9.2.4.5.3.2.
Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1.
Market
Estimation, 2015 - 2020
9.2.4.5.4.2.
Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1.
Market
Estimation, 2015 - 2020
9.2.4.5.5.2.
Market
Forecast, 2021 - 2029
9.2.5. Dentistry
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.5.3.
Market
Forecast, 2021 - 2029
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1.
Market
Estimation, 2015 - 2020
9.2.5.5.1.2.
Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1.
Market
Estimation, 2015 - 2020
9.2.5.5.2.2.
Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1.
Market
Estimation, 2015 - 2020
9.2.5.5.3.2.
Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1.
Market
Estimation, 2015 - 2020
9.2.5.5.4.2.
Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1.
Market
Estimation, 2015 - 2020
9.2.5.5.5.2.
Market
Forecast, 2021 - 2029
9.2.6. Otolaryngology
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.6.3.
Market
Forecast, 2021 - 2029
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1.
Market
Estimation, 2015 - 2020
9.2.6.5.1.2.
Market
Forecast, 2021 - 2029
9.2.6.5.2. Europe
9.2.6.5.2.1.
Market
Estimation, 2015 - 2020
9.2.6.5.2.2.
Market
Forecast, 2021 - 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1.
Market
Estimation, 2015 - 2020
9.2.6.5.3.2.
Market
Forecast, 2021 - 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1.
Market
Estimation, 2015 - 2020
9.2.6.5.4.2.
Market
Forecast, 2021 - 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1.
Market
Estimation, 2015 - 2020
9.2.6.5.5.2.
Market
Forecast, 2021 - 2029
9.2.7. Neurosurgery
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.7.3.
Market
Forecast, 2021 - 2029
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1.
Market
Estimation, 2015 - 2020
9.2.7.5.1.2.
Market
Forecast, 2021 - 2029
9.2.7.5.2. Europe
9.2.7.5.2.1.
Market
Estimation, 2015 - 2020
9.2.7.5.2.2.
Market
Forecast, 2021 - 2029
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1.
Market
Estimation, 2015 - 2020
9.2.7.5.3.2.
Market
Forecast, 2021 - 2029
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1.
Market
Estimation, 2015 - 2020
9.2.7.5.4.2.
Market
Forecast, 2021 - 2029
9.2.7.5.5. Latin America
9.2.7.5.5.1.
Market
Estimation, 2015 - 2020
9.2.7.5.5.2.
Market
Forecast, 2021 - 2029
9.2.8. Ophthalmology
9.2.8.1.
Definition
9.2.8.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.8.3.
Market
Forecast, 2021 - 2029
9.2.8.4.
Compound
Annual Growth Rate (CAGR)
9.2.8.5.
Regional
Bifurcation
9.2.8.5.1. North America
9.2.8.5.1.1.
Market
Estimation, 2015 - 2020
9.2.8.5.1.2.
Market
Forecast, 2021 - 2029
9.2.8.5.2. Europe
9.2.8.5.2.1.
Market
Estimation, 2015 - 2020
9.2.8.5.2.2.
Market
Forecast, 2021 - 2029
9.2.8.5.3. Asia Pacific
9.2.8.5.3.1.
Market
Estimation, 2015 - 2020
9.2.8.5.3.2.
Market
Forecast, 2021 - 2029
9.2.8.5.4. Middle East and Africa
9.2.8.5.4.1.
Market
Estimation, 2015 - 2020
9.2.8.5.4.2.
Market
Forecast, 2021 - 2029
9.2.8.5.5. Latin America
9.2.8.5.5.1.
Market
Estimation, 2015 - 2020
9.2.8.5.5.2.
Market
Forecast, 2021 - 2029
9.2.9. Urology
9.2.9.1.
Definition
9.2.9.2.
Market
Estimation and Penetration, 2015 - 2020
9.2.9.3.
Market
Forecast, 2021 - 2029
9.2.9.4.
Compound
Annual Growth Rate (CAGR)
9.2.9.5.
Regional
Bifurcation
9.2.9.5.1. North America
9.2.9.5.1.1.
Market
Estimation, 2015 - 2020
9.2.9.5.1.2.
Market
Forecast, 2021 - 2029
9.2.9.5.2. Europe
9.2.9.5.2.1.
Market
Estimation, 2015 - 2020
9.2.9.5.2.2.
Market
Forecast, 2021 - 2029
9.2.9.5.3. Asia Pacific
9.2.9.5.3.1.
Market
Estimation, 2015 - 2020
9.2.9.5.3.2.
Market
Forecast, 2021 - 2029
9.2.9.5.4. Middle East and Africa
9.2.9.5.4.1.
Market
Estimation, 2015 - 2020
9.2.9.5.4.2.
Market
Forecast, 2021 - 2029
9.2.9.5.5. Latin America
9.2.9.5.5.1.
Market
Estimation, 2015 - 2020
9.2.9.5.5.2.
Market
Forecast, 2021 - 2029
9.2.10. Prolotherapy
9.2.10.1. Definition
9.2.10.2. Market Estimation and Penetration, 2015 -
2020
9.2.10.3. Market Forecast, 2021 - 2029
9.2.10.4. Compound Annual Growth Rate (CAGR)
9.2.10.5. Regional Bifurcation
9.2.10.5.1. North America
9.2.10.5.1.1.
Market
Estimation, 2015 - 2020
9.2.10.5.1.2.
Market
Forecast, 2021 - 2029
9.2.10.5.2. Europe
9.2.10.5.2.1.
Market
Estimation, 2015 - 2020
9.2.10.5.2.2.
Market
Forecast, 2021 - 2029
9.2.10.5.3. Asia Pacific
9.2.10.5.3.1.
Market
Estimation, 2015 - 2020
9.2.10.5.3.2.
Market
Forecast, 2021 - 2029
9.2.10.5.4. Middle East and Africa
9.2.10.5.4.1.
Market
Estimation, 2015 - 2020
9.2.10.5.4.2.
Market
Forecast, 2021 - 2029
9.2.10.5.5. Latin America
9.2.10.5.5.1.
Market
Estimation, 2015 - 2020
9.2.10.5.5.2.
Market
Forecast, 2021 - 2029
9.2.11. Cardiothoracic
9.2.11.1. Definition
9.2.11.2. Market Estimation and Penetration, 2015 -
2020
9.2.11.3. Market Forecast, 2021 - 2029
9.2.11.4. Compound Annual Growth Rate (CAGR)
9.2.11.5. Regional Bifurcation
9.2.11.5.1. North America
9.2.11.5.1.1.
Market
Estimation, 2015 - 2020
9.2.11.5.1.2.
Market
Forecast, 2021 - 2029
9.2.11.5.2. Europe
9.2.11.5.2.1.
Market
Estimation, 2015 - 2020
9.2.11.5.2.2.
Market
Forecast, 2021 - 2029
9.2.11.5.3. Asia Pacific
9.2.11.5.3.1.
Market
Estimation, 2015 - 2020
9.2.11.5.3.2.
Market
Forecast, 2021 - 2029
9.2.11.5.4. Middle East and Africa
9.2.11.5.4.1.
Market
Estimation, 2015 - 2020
9.2.11.5.4.2.
Market
Forecast, 2021 - 2029
9.2.11.5.5. Latin America
9.2.11.5.5.1.
Market
Estimation, 2015 - 2020
9.2.11.5.5.2.
Market
Forecast, 2021 - 2029
9.2.12. Maxillofacial surgery
9.2.12.1. Definition
9.2.12.2. Market Estimation and Penetration, 2015 -
2020
9.2.12.3. Market Forecast, 2021 - 2029
9.2.12.4. Compound Annual Growth Rate (CAGR)
9.2.12.5. Regional Bifurcation
9.2.12.5.1. North America
9.2.12.5.1.1.
Market
Estimation, 2015 - 2020
9.2.12.5.1.2.
Market
Forecast, 2021 - 2029
9.2.12.5.2. Europe
9.2.12.5.2.1.
Market
Estimation, 2015 - 2020
9.2.12.5.2.2.
Market
Forecast, 2021 - 2029
9.2.12.5.3. Asia Pacific
9.2.12.5.3.1.
Market
Estimation, 2015 - 2020
9.2.12.5.3.2.
Market
Forecast, 2021 - 2029
9.2.12.5.4. Middle East and Africa
9.2.12.5.4.1.
Market
Estimation, 2015 - 2020
9.2.12.5.4.2.
Market
Forecast, 2021 - 2029
9.2.12.5.5. Latin America
9.2.12.5.5.1.
Market
Estimation, 2015 - 2020
9.2.12.5.5.2.
Market
Forecast, 2021 - 2029
9.2.13. Others
9.2.13.1. Definition
9.2.13.2. Market Estimation and Penetration, 2015 -
2020
9.2.13.3. Market Forecast, 2021 - 2029
9.2.13.4. Compound Annual Growth Rate (CAGR)
9.2.13.5. Regional Bifurcation
9.2.13.5.1. North America
9.2.13.5.1.1.
Market
Estimation, 2015 - 2020
9.2.13.5.1.2.
Market
Forecast, 2021 - 2029
9.2.13.5.2. Europe
9.2.13.5.2.1.
Market
Estimation, 2015 - 2020
9.2.13.5.2.2.
Market
Forecast, 2021 - 2029
9.2.13.5.3. Asia Pacific
9.2.13.5.3.1.
Market
Estimation, 2015 - 2020
9.2.13.5.3.2.
Market
Forecast, 2021 - 2029
9.2.13.5.4. Middle East and Africa
9.2.13.5.4.1.
Market
Estimation, 2015 - 2020
9.2.13.5.4.2.
Market
Forecast, 2021 - 2029
9.2.13.5.5. Latin America
9.2.13.5.5.1.
Market
Estimation, 2015 - 2020
9.2.13.5.5.2.
Market
Forecast, 2021 - 2029
9.3. Key Segment for Channeling Investments
9.3.1. By Application
10. Global Platelet Rich Plasma Market Analysis
and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1.
Market
Estimation, 2015 - 2020
10.2.1.5.1.2.
Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1.
Market
Estimation, 2015 - 2020
10.2.1.5.2.2.
Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1.
Market
Estimation, 2015 - 2020
10.2.1.5.3.2.
Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1.
Market
Estimation, 2015 - 2020
10.2.1.5.4.2.
Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1.
Market
Estimation, 2015 - 2020
10.2.1.5.5.2.
Market
Forecast, 2021 - 2029
10.2.2. Clinics
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1.
Market
Estimation, 2015 - 2020
10.2.2.5.1.2.
Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1.
Market
Estimation, 2015 - 2020
10.2.2.5.2.2.
Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1.
Market
Estimation, 2015 - 2020
10.2.2.5.3.2.
Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1.
Market
Estimation, 2015 - 2020
10.2.2.5.4.2.
Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1.
Market
Estimation, 2015 - 2020
10.2.2.5.5.2.
Market
Forecast, 2021 - 2029
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1.
Market
Estimation, 2015 - 2020
10.2.3.5.1.2.
Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1.
Market
Estimation, 2015 - 2020
10.2.3.5.2.2.
Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1.
Market
Estimation, 2015 - 2020
10.2.3.5.3.2.
Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1.
Market
Estimation, 2015 - 2020
10.2.3.5.4.2.
Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1.
Market
Estimation, 2015 - 2020
10.2.3.5.5.2.
Market
Forecast, 2021 - 2029
10.3. Key Segment for Channeling Investments
10.3.1. By End Use
11. North America Platelet Rich Plasma Market Analysis
and Forecasts, 2021 - 2029
11.1. Overview
11.1.1. North America Platelet Rich Plasma Market
Revenue (US$ Mn)
11.2. North America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
11.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
11.2.3. Pure Platelet-Rich Fibrin (P-PRF)
11.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
11.3. North America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
11.3.1. Orthopaedics
11.3.2. Sports medicine
11.3.3. Wound healing
11.3.4. Aesthetic surgery
11.3.5. Dentistry
11.3.6. Otolaryngology
11.3.7. Neurosurgery
11.3.8. Ophthalmology
11.3.9. Urology
11.3.10. Prolotherapy
11.3.11. Cardiothoracic
11.3.12. Maxillofacial surgery
11.3.13. Others
11.4. North America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. North America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By Type
11.5.1.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
11.5.1.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
11.5.1.1.3. Pure Platelet-Rich Fibrin (P-PRF)
11.5.1.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
11.5.1.2. U.S Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By Application
11.5.1.2.1. Orthopaedics
11.5.1.2.2. Sports medicine
11.5.1.2.3. Wound healing
11.5.1.2.4. Aesthetic surgery
11.5.1.2.5. Dentistry
11.5.1.2.6. Otolaryngology
11.5.1.2.7. Neurosurgery
11.5.1.2.8. Ophthalmology
11.5.1.2.9. Urology
11.5.1.2.10. Prolotherapy
11.5.1.2.11. Cardiothoracic
11.5.1.2.12. Maxillofacial surgery
11.5.1.2.13. Others
11.5.1.3. U.S Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By End Use
11.5.1.3.1. Hospitals
11.5.1.3.2. Clinics
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.2.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
11.5.2.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
11.5.2.1.3. Pure Platelet-Rich Fibrin (P-PRF)
11.5.2.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
11.5.2.2. Canada Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
11.5.2.2.1. Orthopaedics
11.5.2.2.2. Sports medicine
11.5.2.2.3. Wound healing
11.5.2.2.4. Aesthetic surgery
11.5.2.2.5. Dentistry
11.5.2.2.6. Otolaryngology
11.5.2.2.7. Neurosurgery
11.5.2.2.8. Ophthalmology
11.5.2.2.9. Urology
11.5.2.2.10. Prolotherapy
11.5.2.2.11. Cardiothoracic
11.5.2.2.12. Maxillofacial surgery
11.5.2.2.13. Others
11.5.2.3. Canada Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
11.5.2.3.1. Hospitals
11.5.2.3.2. Clinics
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
11.5.3.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
11.5.3.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
11.5.3.1.3. Pure Platelet-Rich Fibrin (P-PRF)
11.5.3.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
11.5.3.2. Mexico Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
11.5.3.2.1. Orthopaedics
11.5.3.2.2. Sports medicine
11.5.3.2.3. Wound healing
11.5.3.2.4. Aesthetic surgery
11.5.3.2.5. Dentistry
11.5.3.2.6. Otolaryngology
11.5.3.2.7. Neurosurgery
11.5.3.2.8. Ophthalmology
11.5.3.2.9. Urology
11.5.3.2.10. Prolotherapy
11.5.3.2.11. Cardiothoracic
11.5.3.2.12. Maxillofacial surgery
11.5.3.2.13. Others
11.5.3.3. Mexico Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
11.5.3.3.1. Hospitals
11.5.3.3.2. Clinics
11.5.3.3.3. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Type
11.5.4.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
11.5.4.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
11.5.4.1.3. Pure Platelet-Rich Fibrin (P-PRF)
11.5.4.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
11.5.4.2. Rest of North America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1. Orthopaedics
11.5.4.2.2. Sports medicine
11.5.4.2.3. Wound healing
11.5.4.2.4. Aesthetic surgery
11.5.4.2.5. Dentistry
11.5.4.2.6. Otolaryngology
11.5.4.2.7. Neurosurgery
11.5.4.2.8. Ophthalmology
11.5.4.2.9. Urology
11.5.4.2.10. Prolotherapy
11.5.4.2.11. Cardiothoracic
11.5.4.2.12. Maxillofacial surgery
11.5.4.2.13. Others
11.5.4.3. Rest of North America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By End Use
11.5.4.3.1. Hospitals
11.5.4.3.2. Clinics
11.5.4.3.3. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Type
11.6.3. By Application
11.6.4. By End Use
12. Europe Platelet Rich Plasma Market Analysis
and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. Europe Platelet Rich Plasma Market Revenue (US$
Mn)
12.2. Europe Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.2.3. Pure Platelet-Rich Fibrin (P-PRF)
12.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.3. Europe Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.3.1. Orthopaedics
12.3.2. Sports medicine
12.3.3. Wound healing
12.3.4. Aesthetic surgery
12.3.5. Dentistry
12.3.6. Otolaryngology
12.3.7. Neurosurgery
12.3.8. Ophthalmology
12.3.9. Urology
12.3.10. Prolotherapy
12.3.11. Cardiothoracic
12.3.12. Maxillofacial surgery
12.3.13. Others
12.4. Europe Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Europe Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.1.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.1.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.1.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.1.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.1.2. France Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.1.2.1. Orthopaedics
12.5.1.2.2. Sports medicine
12.5.1.2.3. Wound healing
12.5.1.2.4. Aesthetic surgery
12.5.1.2.5. Dentistry
12.5.1.2.6. Otolaryngology
12.5.1.2.7. Neurosurgery
12.5.1.2.8. Ophthalmology
12.5.1.2.9. Urology
12.5.1.2.10. Prolotherapy
12.5.1.2.11. Cardiothoracic
12.5.1.2.12. Maxillofacial surgery
12.5.1.2.13. Others
12.5.1.3. France Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By End Use
12.5.1.3.1. Hospitals
12.5.1.3.2. Clinics
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The UK Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.2.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.2.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.2.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.2.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.2.2. The UK Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.2.2.1. Orthopaedics
12.5.2.2.2. Sports medicine
12.5.2.2.3. Wound healing
12.5.2.2.4. Aesthetic surgery
12.5.2.2.5. Dentistry
12.5.2.2.6. Otolaryngology
12.5.2.2.7. Neurosurgery
12.5.2.2.8. Ophthalmology
12.5.2.2.9. Urology
12.5.2.2.10. Prolotherapy
12.5.2.2.11. Cardiothoracic
12.5.2.2.12. Maxillofacial surgery
12.5.2.2.13. Others
12.5.2.3. The UK Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
12.5.2.3.1. Hospitals
12.5.2.3.2. Clinics
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.3.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.3.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.3.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.3.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.3.2. Spain Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.3.2.1. Orthopaedics
12.5.3.2.2. Sports medicine
12.5.3.2.3. Wound healing
12.5.3.2.4. Aesthetic surgery
12.5.3.2.5. Dentistry
12.5.3.2.6. Otolaryngology
12.5.3.2.7. Neurosurgery
12.5.3.2.8. Ophthalmology
12.5.3.2.9. Urology
12.5.3.2.10. Prolotherapy
12.5.3.2.11. Cardiothoracic
12.5.3.2.12. Maxillofacial surgery
12.5.3.2.13. Others
12.5.3.3. Spain Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
12.5.3.3.1. Hospitals
12.5.3.3.2. Clinics
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.4.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.4.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.4.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.4.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.4.2. Germany Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.4.2.1. Orthopaedics
12.5.4.2.2. Sports medicine
12.5.4.2.3. Wound healing
12.5.4.2.4. Aesthetic surgery
12.5.4.2.5. Dentistry
12.5.4.2.6. Otolaryngology
12.5.4.2.7. Neurosurgery
12.5.4.2.8. Ophthalmology
12.5.4.2.9. Urology
12.5.4.2.10. Prolotherapy
12.5.4.2.11. Cardiothoracic
12.5.4.2.12. Maxillofacial surgery
12.5.4.2.13. Others
12.5.4.3. Germany Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
12.5.4.3.1. Hospitals
12.5.4.3.2. Clinics
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
12.5.5.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.5.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.5.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.5.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.5.2. Italy Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.5.2.1. Orthopaedics
12.5.5.2.2. Sports medicine
12.5.5.2.3. Wound healing
12.5.5.2.4. Aesthetic surgery
12.5.5.2.5. Dentistry
12.5.5.2.6. Otolaryngology
12.5.5.2.7. Neurosurgery
12.5.5.2.8. Ophthalmology
12.5.5.2.9. Urology
12.5.5.2.10. Prolotherapy
12.5.5.2.11. Cardiothoracic
12.5.5.2.12. Maxillofacial surgery
12.5.5.2.13. Others
12.5.5.3. Italy Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
12.5.5.3.1. Hospitals
12.5.5.3.2. Clinics
12.5.5.3.3. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.6.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.6.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.6.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.6.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.6.2. Nordic Countries Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
12.5.6.2.1. Orthopaedics
12.5.6.2.2. Sports medicine
12.5.6.2.3. Wound healing
12.5.6.2.4. Aesthetic surgery
12.5.6.2.5. Dentistry
12.5.6.2.6. Otolaryngology
12.5.6.2.7. Neurosurgery
12.5.6.2.8. Ophthalmology
12.5.6.2.9. Urology
12.5.6.2.10. Prolotherapy
12.5.6.2.11. Cardiothoracic
12.5.6.2.12. Maxillofacial surgery
12.5.6.2.13. Others
12.5.6.3. Nordic Countries Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
12.5.6.3.1. Hospitals
12.5.6.3.2. Clinics
12.5.6.3.3. Others
12.5.6.4. Nordic Countries Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.7.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.7.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.7.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.7.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.7.2. Benelux Union Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1. Orthopaedics
12.5.7.2.2. Sports medicine
12.5.7.2.3. Wound healing
12.5.7.2.4. Aesthetic surgery
12.5.7.2.5. Dentistry
12.5.7.2.6. Otolaryngology
12.5.7.2.7. Neurosurgery
12.5.7.2.8. Ophthalmology
12.5.7.2.9. Urology
12.5.7.2.10. Prolotherapy
12.5.7.2.11. Cardiothoracic
12.5.7.2.12. Maxillofacial surgery
12.5.7.2.13. Others
12.5.7.3. Benelux Union Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
12.5.7.3.1. Hospitals
12.5.7.3.2. Clinics
12.5.7.3.3. Others
12.5.7.4. Benelux Union Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
12.5.8.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
12.5.8.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
12.5.8.1.3. Pure Platelet-Rich Fibrin (P-PRF)
12.5.8.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
12.5.8.2. Rest of Europe Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
12.5.8.2.1. Orthopaedics
12.5.8.2.2. Sports medicine
12.5.8.2.3. Wound healing
12.5.8.2.4. Aesthetic surgery
12.5.8.2.5. Dentistry
12.5.8.2.6. Otolaryngology
12.5.8.2.7. Neurosurgery
12.5.8.2.8. Ophthalmology
12.5.8.2.9. Urology
12.5.8.2.10. Prolotherapy
12.5.8.2.11. Cardiothoracic
12.5.8.2.12. Maxillofacial surgery
12.5.8.2.13. Others
12.5.8.3. Rest of Europe Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
12.5.8.3.1. Hospitals
12.5.8.3.2. Clinics
12.5.8.3.3. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Type
12.6.3. By Application
12.6.4. By End Use
13. Asia Pacific Platelet Rich Plasma Market
Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Asia Pacific Platelet Rich Plasma Market
Revenue (US$ Mn)
13.2. Asia Pacific Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.2.3. Pure Platelet-Rich Fibrin (P-PRF)
13.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.3. Asia Pacific Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
13.3.1. Orthopaedics
13.3.2. Sports medicine
13.3.3. Wound healing
13.3.4. Aesthetic surgery
13.3.5. Dentistry
13.3.6. Otolaryngology
13.3.7. Neurosurgery
13.3.8. Ophthalmology
13.3.9. Urology
13.3.10. Prolotherapy
13.3.11. Cardiothoracic
13.3.12. Maxillofacial surgery
13.3.13. Others
13.4. Asia Pacific Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Asia Pacific Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.1.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.1.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.1.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.1.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.1.2. China Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.1.2.1. Orthopaedics
13.5.1.2.2. Sports medicine
13.5.1.2.3. Wound healing
13.5.1.2.4. Aesthetic surgery
13.5.1.2.5. Dentistry
13.5.1.2.6. Otolaryngology
13.5.1.2.7. Neurosurgery
13.5.1.2.8. Ophthalmology
13.5.1.2.9. Urology
13.5.1.2.10. Prolotherapy
13.5.1.2.11. Cardiothoracic
13.5.1.2.12. Maxillofacial surgery
13.5.1.2.13. Others
13.5.1.3. China Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
13.5.1.3.1. Hospitals
13.5.1.3.2. Clinics
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.2.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.2.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.2.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.2.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.2.2. Japan Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.2.2.1. Orthopaedics
13.5.2.2.2. Sports medicine
13.5.2.2.3. Wound healing
13.5.2.2.4. Aesthetic surgery
13.5.2.2.5. Dentistry
13.5.2.2.6. Otolaryngology
13.5.2.2.7. Neurosurgery
13.5.2.2.8. Ophthalmology
13.5.2.2.9. Urology
13.5.2.2.10. Prolotherapy
13.5.2.2.11. Cardiothoracic
13.5.2.2.12. Maxillofacial surgery
13.5.2.2.13. Others
13.5.2.3. Japan Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
13.5.2.3.1. Hospitals
13.5.2.3.2. Clinics
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.3.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.3.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.3.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.3.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.3.2. India Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.3.2.1. Orthopaedics
13.5.3.2.2. Sports medicine
13.5.3.2.3. Wound healing
13.5.3.2.4. Aesthetic surgery
13.5.3.2.5. Dentistry
13.5.3.2.6. Otolaryngology
13.5.3.2.7. Neurosurgery
13.5.3.2.8. Ophthalmology
13.5.3.2.9. Urology
13.5.3.2.10. Prolotherapy
13.5.3.2.11. Cardiothoracic
13.5.3.2.12. Maxillofacial surgery
13.5.3.2.13. Others
13.5.3.3. India Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
13.5.3.3.1. Hospitals
13.5.3.3.2. Clinics
13.5.3.3.3. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.4.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.4.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.4.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.4.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.4.2. New Zealand Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
13.5.4.2.1. Orthopaedics
13.5.4.2.2. Sports medicine
13.5.4.2.3. Wound healing
13.5.4.2.4. Aesthetic surgery
13.5.4.2.5. Dentistry
13.5.4.2.6. Otolaryngology
13.5.4.2.7. Neurosurgery
13.5.4.2.8. Ophthalmology
13.5.4.2.9. Urology
13.5.4.2.10. Prolotherapy
13.5.4.2.11. Cardiothoracic
13.5.4.2.12. Maxillofacial surgery
13.5.4.2.13. Others
13.5.4.3. New Zealand Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
13.5.4.3.1. Hospitals
13.5.4.3.2. Clinics
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
13.5.5.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.5.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.5.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.5.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.5.2. Australia Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
13.5.5.2.1. Orthopaedics
13.5.5.2.2. Sports medicine
13.5.5.2.3. Wound healing
13.5.5.2.4. Aesthetic surgery
13.5.5.2.5. Dentistry
13.5.5.2.6. Otolaryngology
13.5.5.2.7. Neurosurgery
13.5.5.2.8. Ophthalmology
13.5.5.2.9. Urology
13.5.5.2.10. Prolotherapy
13.5.5.2.11. Cardiothoracic
13.5.5.2.12. Maxillofacial surgery
13.5.5.2.13. Others
13.5.5.3. Australia Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
13.5.5.3.1. Hospitals
13.5.5.3.2. Clinics
13.5.5.3.3. Others
13.5.6. South Korea
13.5.6.1. South Korea Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.6.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.6.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.6.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.6.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.6.2. South Korea Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
13.5.6.2.1. Orthopaedics
13.5.6.2.2. Sports medicine
13.5.6.2.3. Wound healing
13.5.6.2.4. Aesthetic surgery
13.5.6.2.5. Dentistry
13.5.6.2.6. Otolaryngology
13.5.6.2.7. Neurosurgery
13.5.6.2.8. Ophthalmology
13.5.6.2.9. Urology
13.5.6.2.10. Prolotherapy
13.5.6.2.11. Cardiothoracic
13.5.6.2.12. Maxillofacial surgery
13.5.6.2.13. Others
13.5.6.3. South Korea Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
13.5.6.3.1. Hospitals
13.5.6.3.2. Clinics
13.5.6.3.3. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
13.5.7.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.7.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.7.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.7.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.7.2. Southeast Asia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1. Orthopaedics
13.5.7.2.2. Sports medicine
13.5.7.2.3. Wound healing
13.5.7.2.4. Aesthetic surgery
13.5.7.2.5. Dentistry
13.5.7.2.6. Otolaryngology
13.5.7.2.7. Neurosurgery
13.5.7.2.8. Ophthalmology
13.5.7.2.9. Urology
13.5.7.2.10. Prolotherapy
13.5.7.2.11. Cardiothoracic
13.5.7.2.12. Maxillofacial surgery
13.5.7.2.13. Others
13.5.7.3. Southeast Asia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
13.5.7.3.1. Hospitals
13.5.7.3.2. Clinics
13.5.7.3.3. Others
13.5.7.4. Southeast Asia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Type
13.5.8.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
13.5.8.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
13.5.8.1.3. Pure Platelet-Rich Fibrin (P-PRF)
13.5.8.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
13.5.8.2. Rest of Asia Pacific Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1. Orthopaedics
13.5.8.2.2. Sports medicine
13.5.8.2.3. Wound healing
13.5.8.2.4. Aesthetic surgery
13.5.8.2.5. Dentistry
13.5.8.2.6. Otolaryngology
13.5.8.2.7. Neurosurgery
13.5.8.2.8. Ophthalmology
13.5.8.2.9. Urology
13.5.8.2.10. Prolotherapy
13.5.8.2.11. Cardiothoracic
13.5.8.2.12. Maxillofacial surgery
13.5.8.2.13. Others
13.5.8.3. Rest of Asia Pacific Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.8.3.1. Hospitals
13.5.8.3.2. Clinics
13.5.8.3.3. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Type
13.6.3. By Application
13.6.4. By End Use
14. Middle East and Africa Platelet Rich Plasma
Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Middle East and Africa Platelet Rich Plasma
Market Revenue (US$ Mn)
14.2. Middle East and Africa Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.2.3. Pure Platelet-Rich Fibrin (P-PRF)
14.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.3. Middle East and Africa Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Orthopaedics
14.3.2. Sports medicine
14.3.3. Wound healing
14.3.4. Aesthetic surgery
14.3.5. Dentistry
14.3.6. Otolaryngology
14.3.7. Neurosurgery
14.3.8. Ophthalmology
14.3.9. Urology
14.3.10. Prolotherapy
14.3.11. Cardiothoracic
14.3.12. Maxillofacial surgery
14.3.13. Others
14.4. Middle East and Africa Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By End Use
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Others
14.5. Middle East and Africa Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.1.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.1.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.1.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.1.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.1.2. Saudi Arabia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.1.2.1. Orthopaedics
14.5.1.2.2. Sports medicine
14.5.1.2.3. Wound healing
14.5.1.2.4. Aesthetic surgery
14.5.1.2.5. Dentistry
14.5.1.2.6. Otolaryngology
14.5.1.2.7. Neurosurgery
14.5.1.2.8. Ophthalmology
14.5.1.2.9. Urology
14.5.1.2.10. Prolotherapy
14.5.1.2.11. Cardiothoracic
14.5.1.2.12. Maxillofacial surgery
14.5.1.2.13. Others
14.5.1.3. Saudi Arabia Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
14.5.1.3.1. Hospitals
14.5.1.3.2. Clinics
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By Type
14.5.2.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.2.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.2.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.2.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.2.2. UAE Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By Application
14.5.2.2.1. Orthopaedics
14.5.2.2.2. Sports medicine
14.5.2.2.3. Wound healing
14.5.2.2.4. Aesthetic surgery
14.5.2.2.5. Dentistry
14.5.2.2.6. Otolaryngology
14.5.2.2.7. Neurosurgery
14.5.2.2.8. Ophthalmology
14.5.2.2.9. Urology
14.5.2.2.10. Prolotherapy
14.5.2.2.11. Cardiothoracic
14.5.2.2.12. Maxillofacial surgery
14.5.2.2.13. Others
14.5.2.3. UAE Platelet Rich Plasma Market Revenue (US$
Mn) and Forecasts, By End Use
14.5.2.3.1. Hospitals
14.5.2.3.2. Clinics
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.3.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.3.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.3.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.3.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.3.2. Egypt Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
14.5.3.2.1. Orthopaedics
14.5.3.2.2. Sports medicine
14.5.3.2.3. Wound healing
14.5.3.2.4. Aesthetic surgery
14.5.3.2.5. Dentistry
14.5.3.2.6. Otolaryngology
14.5.3.2.7. Neurosurgery
14.5.3.2.8. Ophthalmology
14.5.3.2.9. Urology
14.5.3.2.10. Prolotherapy
14.5.3.2.11. Cardiothoracic
14.5.3.2.12. Maxillofacial surgery
14.5.3.2.13. Others
14.5.3.3. Egypt Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
14.5.3.3.1. Hospitals
14.5.3.3.2. Clinics
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
14.5.4.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.4.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.4.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.4.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.4.2. Kuwait Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
14.5.4.2.1. Orthopaedics
14.5.4.2.2. Sports medicine
14.5.4.2.3. Wound healing
14.5.4.2.4. Aesthetic surgery
14.5.4.2.5. Dentistry
14.5.4.2.6. Otolaryngology
14.5.4.2.7. Neurosurgery
14.5.4.2.8. Ophthalmology
14.5.4.2.9. Urology
14.5.4.2.10. Prolotherapy
14.5.4.2.11. Cardiothoracic
14.5.4.2.12. Maxillofacial surgery
14.5.4.2.13. Others
14.5.4.3. Kuwait Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
14.5.4.3.1. Hospitals
14.5.4.3.2. Clinics
14.5.4.3.3. Others
14.5.5. South Africa
14.5.5.1. South Africa Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
14.5.5.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.5.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.5.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.5.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.5.2. South Africa Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
14.5.5.2.1. Orthopaedics
14.5.5.2.2. Sports medicine
14.5.5.2.3. Wound healing
14.5.5.2.4. Aesthetic surgery
14.5.5.2.5. Dentistry
14.5.5.2.6. Otolaryngology
14.5.5.2.7. Neurosurgery
14.5.5.2.8. Ophthalmology
14.5.5.2.9. Urology
14.5.5.2.10. Prolotherapy
14.5.5.2.11. Cardiothoracic
14.5.5.2.12. Maxillofacial surgery
14.5.5.2.13. Others
14.5.5.3. South Africa Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
14.5.5.3.1. Hospitals
14.5.5.3.2. Clinics
14.5.5.3.3. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Platelet
Rich Plasma Market Revenue (US$ Mn) and Forecasts, By Type
14.5.6.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
14.5.6.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
14.5.6.1.3. Pure Platelet-Rich Fibrin (P-PRF)
14.5.6.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
14.5.6.2. Rest of Middle East & Africa Platelet
Rich Plasma Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1. Orthopaedics
14.5.6.2.2. Sports medicine
14.5.6.2.3. Wound healing
14.5.6.2.4. Aesthetic surgery
14.5.6.2.5. Dentistry
14.5.6.2.6. Otolaryngology
14.5.6.2.7. Neurosurgery
14.5.6.2.8. Ophthalmology
14.5.6.2.9. Urology
14.5.6.2.10. Prolotherapy
14.5.6.2.11. Cardiothoracic
14.5.6.2.12. Maxillofacial surgery
14.5.6.2.13. Others
14.5.6.3. Rest of Middle East & Africa Platelet
Rich Plasma Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.6.3.1. Hospitals
14.5.6.3.2. Clinics
14.5.6.3.3. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Type
14.6.3. By Application
14.6.4. By End Use
15. Latin America Platelet Rich Plasma Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Latin America Platelet Rich Plasma Market
Revenue (US$ Mn)
15.2. Latin America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
15.2.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
15.2.3. Pure Platelet-Rich Fibrin (P-PRF)
15.2.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
15.3. Latin America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Orthopaedics
15.3.2. Sports medicine
15.3.3. Wound healing
15.3.4. Aesthetic surgery
15.3.5. Dentistry
15.3.6. Otolaryngology
15.3.7. Neurosurgery
15.3.8. Ophthalmology
15.3.9. Urology
15.3.10. Prolotherapy
15.3.11. Cardiothoracic
15.3.12. Maxillofacial surgery
15.3.13. Others
15.4. Latin America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By End Use
15.4.1. Hospitals
15.4.2. Clinics
15.4.3. Others
15.5. Latin America Platelet Rich Plasma Market
Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.1.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
15.5.1.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
15.5.1.1.3. Pure Platelet-Rich Fibrin (P-PRF)
15.5.1.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
15.5.1.2. Brazil Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
15.5.1.2.1. Orthopaedics
15.5.1.2.2. Sports medicine
15.5.1.2.3. Wound healing
15.5.1.2.4. Aesthetic surgery
15.5.1.2.5. Dentistry
15.5.1.2.6. Otolaryngology
15.5.1.2.7. Neurosurgery
15.5.1.2.8. Ophthalmology
15.5.1.2.9. Urology
15.5.1.2.10. Prolotherapy
15.5.1.2.11. Cardiothoracic
15.5.1.2.12. Maxillofacial surgery
15.5.1.2.13. Others
15.5.1.3. Brazil Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
15.5.1.3.1. Hospitals
15.5.1.3.2. Clinics
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Type
15.5.2.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
15.5.2.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
15.5.2.1.3. Pure Platelet-Rich Fibrin (P-PRF)
15.5.2.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
15.5.2.2. Argentina Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By Application
15.5.2.2.1. Orthopaedics
15.5.2.2.2. Sports medicine
15.5.2.2.3. Wound healing
15.5.2.2.4. Aesthetic surgery
15.5.2.2.5. Dentistry
15.5.2.2.6. Otolaryngology
15.5.2.2.7. Neurosurgery
15.5.2.2.8. Ophthalmology
15.5.2.2.9. Urology
15.5.2.2.10. Prolotherapy
15.5.2.2.11. Cardiothoracic
15.5.2.2.12. Maxillofacial surgery
15.5.2.2.13. Others
15.5.2.3. Argentina Platelet Rich Plasma Market Revenue
(US$ Mn) and Forecasts, By End Use
15.5.2.3.1. Hospitals
15.5.2.3.2. Clinics
15.5.2.3.3. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Type
15.5.3.1.1. Pure Platelet-Rich Plasma or Pure PRP (P-PRP)
15.5.3.1.2. Leukocyte and Platelet-Rich Plasma (L-PRP)
15.5.3.1.3. Pure Platelet-Rich Fibrin (P-PRF)
15.5.3.1.4. Leukocyte and Platelet-Rich Fibrin (L-PRF)
15.5.3.2. Rest of Latin America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.2.1. Orthopaedics
15.5.3.2.2. Sports medicine
15.5.3.2.3. Wound healing
15.5.3.2.4. Aesthetic surgery
15.5.3.2.5. Dentistry
15.5.3.2.6. Otolaryngology
15.5.3.2.7. Neurosurgery
15.5.3.2.8. Ophthalmology
15.5.3.2.9. Urology
15.5.3.2.10. Prolotherapy
15.5.3.2.11. Cardiothoracic
15.5.3.2.12. Maxillofacial surgery
15.5.3.2.13. Others
15.5.3.3. Rest of Latin America Platelet Rich Plasma
Market Revenue (US$ Mn) and Forecasts, By End Use
15.5.3.3.1. Hospitals
15.5.3.3.2. Clinics
15.5.3.3.3. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Type
15.6.3. By Application
15.6.4. By End Use
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2020
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. AdvaCare Pharma
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Atlas Health Medical Group
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. DePuy Synthes
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. EmCyte Corporation
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Glofinn America, LLC
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Medsor Impex
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. PRP Labs
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Stryker
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Terumo BCT, Inc.
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Zimmer Biomet
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Other Market Participants
18.
Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.